Introduction: This quiz collection on the informed consent process and documentation is designed for M.Pharm students to strengthen understanding of ethical, regulatory, and practical aspects of obtaining and recording informed consent in clinical research. It covers core concepts such as consent elements, capacity assessment, vulnerable populations, assent, re-consent, emergency waivers, electronic consent, translation accuracy, and documentation retention. Each question emphasizes scenarios and documentation expectations aligned with ICH-GCP and common regulatory frameworks, helping students apply principles to real-world trial conduct, ethics committee interactions, and source/essential document management. Use these MCQs to evaluate knowledge, identify learning gaps, and prepare for regulatory examinations and clinical research practice.
Q1. Which element is NOT considered an essential component of an ethically valid informed consent?
- Explanation of study purpose, procedures, risks and benefits
- Voluntary nature of participation and right to withdraw
- Guarantee of direct therapeutic benefit to each participant
- Information about confidentiality and alternative treatments
Correct Answer: Guarantee of direct therapeutic benefit to each participant
Q2. Who is primarily responsible for ensuring that consent is properly obtained and documented at a trial site?
- Study sponsor
- Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
- Principal investigator (PI)
- Monitor (CRA)
Correct Answer: Principal investigator (PI)
Q3. In the context of informed consent, what does “capacity” most directly refer to?
- The legal age of the participant
- The participant’s competence to understand relevant information and make an informed decision
- A formal psychiatric diagnosis
- Permission granted by a legally authorized representative
Correct Answer: The participant’s competence to understand relevant information and make an informed decision
Q4. When is re-consent required during a clinical trial?
- Only when the study reaches its primary endpoint
- When there are changes to the protocol or new safety information that may affect participants’ willingness to continue
- Never; initial consent covers the entire study
- Only at the time of final study publication
Correct Answer: When there are changes to the protocol or new safety information that may affect participants’ willingness to continue
Q5. Which document is considered an “essential document” under ICH-GCP for proving informed consent was obtained?
- Participant’s medical chart with AE entries only
- Signed and dated informed consent form (ICF) retained in source and trial master file (TMF)
- Investigator’s personal notes about conversations
- Study budget and payment receipts
Correct Answer: Signed and dated informed consent form (ICF) retained in source and trial master file (TMF)
Q6. Which practice is appropriate when using translated consent forms for non‑English speaking participants?
- Use back-translation and confirm accuracy with a qualified translator or local ethics committee
- Rely only on the investigator’s verbal translation during the visit
- Translate only the risks section and leave the rest in English
- Use machine translation without review
Correct Answer: Use back-translation and confirm accuracy with a qualified translator or local ethics committee
Q7. What is the primary ethical justification for obtaining assent from minors in addition to parental/guardian consent?
- To satisfy administrative requirements only
- To respect the developing autonomy and involvement of the minor in decision-making
- Because assent is legally binding without parental consent
- To exempt the investigator from obtaining parental consent
Correct Answer: To respect the developing autonomy and involvement of the minor in decision-making
Q8. Under what circumstances can a waiver of informed consent be ethically and regulatorily acceptable?
- For all interventional trials where the sponsor deems it unnecessary
- For minimal-risk research or emergency research when specific regulatory criteria for waiver or deferred consent are met and approved by an IRB/IEC
- When participants are illiterate
- When the cost of obtaining consent is prohibitive
Correct Answer: For minimal-risk research or emergency research when specific regulatory criteria for waiver or deferred consent are met and approved by an IRB/IEC
Q9. Which of the following best describes “documented oral consent” procedures?
- Oral consent without any record is sufficient
- Oral consent can be used with a witness who signs a short form consent and a written summary is provided
- Oral consent replaces the need for IRB approval
- Only audio recordings without any signed forms are acceptable
Correct Answer: Oral consent can be used with a witness who signs a short form consent and a written summary is provided
Q10. What is a key documentation step when a participant decides to withdraw from a clinical study?
- Destroy all previously collected data
- Document the withdrawal in source records, note reason if given, and process data/sample disposition per consent and protocol
- Obtain a signed affidavit forcing continuation
- Remove the participant’s name from all trial records
Correct Answer: Document the withdrawal in source records, note reason if given, and process data/sample disposition per consent and protocol
Q11. Which statement about electronic informed consent (e‑consent) is correct?
- E‑consent is always preferable and does not require approval from the IRB/IEC
- E‑consent systems must ensure identity verification, secure storage, version control, and the ability to provide human interaction if required
- Once uploaded, e‑consent forms need no audit trail
- E‑consent cannot include multimedia explanations
Correct Answer: E‑consent systems must ensure identity verification, secure storage, version control, and the ability to provide human interaction if required
Q12. Which record should be kept to demonstrate that the informed consent process was conducted appropriately at each visit?
- Only the signed consent form in a file cabinet
- Source documentation such as consent discussion notes, dated signatures, witness signatures (if applicable), and copies of the ICF
- Only a log of phone calls with participants
- Study billing invoices
Correct Answer: Source documentation such as consent discussion notes, dated signatures, witness signatures (if applicable), and copies of the ICF
Q13. What should be done if a participant is unable to sign the consent form due to physical disability?
- Exclude the participant automatically
- Allow a legal representative to sign without documenting the reason
- Use an impartial witness to attest to the participant’s oral consent and document the reason the participant could not sign
- Have the investigator sign on behalf of the participant without witness
Correct Answer: Use an impartial witness to attest to the participant’s oral consent and document the reason the participant could not sign
Q14. Which action is required by the IRB/IEC regarding informed consent forms before participant enrollment begins?
- Approve the ICF and any recruitment materials, including exact wording and translations
- Only review the protocol but not the consent form
- Allow the sponsor to finalize the ICF without their review
- Approve verbal scripts only, not written forms
Correct Answer: Approve the ICF and any recruitment materials, including exact wording and translations
Q15. In a blinded randomized clinical trial, what important consent-related information must still be provided to participants?
- The exact treatment assignment will be disclosed immediately
- Explanation about randomization, blinding, potential for placebo or comparator, and procedures for unblinding in emergencies
- That blinding removes all risks from participating
- No mention of randomization is necessary to preserve blinding
Correct Answer: Explanation about randomization, blinding, potential for placebo or comparator, and procedures for unblinding in emergencies
Q16. How long should informed consent documentation typically be retained after study completion, according to common regulatory expectations?
- Until the next investigator meeting
- For a period specified by regulation (commonly at least 2–15 years depending on jurisdiction) or as defined by sponsor contract and local law
- Only until database lock
- One month after the last patient visit
Correct Answer: For a period specified by regulation (commonly at least 2–15 years depending on jurisdiction) or as defined by sponsor contract and local law
Q17. Which of the following is a proper way to document that a participant received adequate opportunity to ask questions before consenting?
- Note in the source file that the participant had time to ask questions, list key questions asked and responses, and indicate date/time of discussion
- Assume absence of questions implies understanding
- Rely solely on the participant’s signature as proof
- Record only the investigator’s opinion that the participant seemed satisfied
Correct Answer: Note in the source file that the participant had time to ask questions, list key questions asked and responses, and indicate date/time of discussion
Q18. When a legally authorized representative (LAR) provides consent, what additional step is often required?
- No additional records are needed
- Document the relationship and authority of the LAR, and obtain assent from the participant when possible
- Require a court order in all cases
- Exclude the participant from the study automatically
Correct Answer: Document the relationship and authority of the LAR, and obtain assent from the participant when possible
Q19. Which approach is appropriate when significant new safety information emerges after participants have consented?
- Keep participants uninformed to avoid alarm
- Inform participants promptly, update the ICF, obtain re-consent where required, and notify the IRB/IEC and regulatory authorities as applicable
- Only notify the sponsor and not participants
- Wait until study completion to communicate changes
Correct Answer: Inform participants promptly, update the ICF, obtain re-consent where required, and notify the IRB/IEC and regulatory authorities as applicable
Q20. What is the best practice for tracking versions of the informed consent form used at a site?
- Keep only the latest version and discard previous ones
- Maintain a consent form version log with dates approved by IRB/IEC, version numbers, and records of which participants signed which version
- Record versions only in the sponsor’s archive
- Use file names only without documenting approval dates
Correct Answer: Maintain a consent form version log with dates approved by IRB/IEC, version numbers, and records of which participants signed which version
